ADIA joins Corona Remedies block deal

Abu Dhabi Investment Authority and a group of institutional investors have bought a 7.3 per cent stake in Corona Remedies for ₹777 crore, marking a sizeable secondary market transaction in the Ahmedabad-based drugmaker months after its stock market debut.
The shares changed hands through block deals on the National Stock Exchange, with the transaction executed at ₹1,730 a share. The deal involved about 44.9 lakh shares, with private equity investor ChrysCapital, through its affiliate Sepia Investments, and Anchor Partners selling part of their holdings. ADIA bought 39,130 shares, while other buyers included Aberdeen Group, Factory Mutual Insurance Company, HDFC Mutual Fund, Kotak Mahindra Mutual Fund, Ashoka WhiteOak and other funds.

Corona Remedies’ shares rose nearly 3 per cent after the transaction, trading around ₹1,840 on the NSE, as the market read the entry of large domestic and overseas institutions as a vote of confidence in the company’s branded formulations business. The block deal valued the stake at a premium to the company’s public issue price band of ₹1,008-₹1,062 a share in December 2025, underlining the strong post-listing performance of the stock.

Sepia Investments sold 43.28 lakh shares, equal to about 7.07 per cent of Corona Remedies’ equity, for around ₹748.9 crore. Anchor Partners offloaded 1.61 lakh shares, or 0.26 per cent, for about ₹28 crore. Sepia’s stake fell to 12.69 per cent from 19.76 per cent after the sale, while the wider ownership base brought more institutional depth to the company’s shareholder register.

The transaction is also a partial exit for early financial investors who backed Corona Remedies before its public listing. For buyers, the attraction lies in a domestic formulations franchise with established brands across women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic categories. The company has positioned itself in segments with higher repeat prescription potential and relatively stronger pricing resilience than low-margin commodity generics.

Corona Remedies reported revenue growth of about 17 per cent in the financial year ended March 2026, while profit after tax rose about 33 per cent. Its full-year revenue crossed ₹1,400 crore, supported by growth in chronic and sub-chronic therapies, brand-led marketing and wider distribution. The company’s earlier public offer was entirely an offer for sale, meaning the proceeds went to existing shareholders rather than to the company.

The drugmaker was ranked among the top 30 pharmaceutical companies in the domestic pharmaceutical market by sales before its listing. Women’s healthcare is one of its strongest verticals, followed by cardio-diabeto, pain management and urology. Its brand portfolio includes products targeted at specialist doctors, a strategy that has helped it command higher prescription visibility in selected therapies.

The stake purchase comes at a time when pharmaceutical companies with strong domestic franchises are drawing investor interest. Companies focused on branded formulations have benefited from rising healthcare consumption, deeper insurance penetration, higher diagnosis rates for chronic conditions and stronger prescription volumes in urban and semi-urban markets. The domestic pharmaceutical market has also been less exposed to some of the pricing and regulatory volatility faced by export-heavy generic drugmakers.

ADIA’s participation fits a broader pattern of Gulf sovereign capital seeking exposure to healthcare, pharmaceuticals, financial services, infrastructure and consumer platforms across growth markets. The Abu Dhabi fund has built a diversified global portfolio and has been active in private equity, listed equities, real estate and alternatives. Its entry into Corona Remedies, though modest in percentage terms, adds to institutional interest in healthcare businesses with predictable cash flows and long-term demand visibility.

For Corona Remedies, the deal improves public float quality and may support market liquidity. Greater institutional ownership can also bring closer scrutiny of margins, product concentration, compliance, capital allocation and future acquisition strategy. The company’s next phase will be measured against its ability to maintain growth while protecting profitability in a market where promotional expenses, field-force productivity and doctor engagement remain critical.

The transaction also highlights how block deals have become an important route for private equity funds to monetise stakes after listings. Rather than waiting for gradual market sales, large shareholders can exit or pare exposure through negotiated exchange transactions that allow institutional buyers to acquire sizeable positions in a single trading window. Such deals can reduce overhang when executed cleanly, though they also put focus on valuation sustainability after the initial market response.